Company intelligence / Profile preview

RevitaLid Pharmaceutical

Yardley, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

RevitaLid Pharmaceutical was a clinical-stage biopharmaceutical company dedicated to developing and commercializing ophthalmic products. The company's primary focus was the development of RVL-101 (oxymetazoline hydrochloride ophthalmic solution, 0.1%), a first-in-class pharmacological treatment for acquired blepharoptosis, commonly known as droopy eyelid. In 2017, RevitaLid was acquired by Osmotica Pharmaceuticals, which successfully moved the candidate through Phase 3 trials. The drug was subsequently approved by the FDA in 2020 under the brand name Upneeq, becoming the first and only non-surgical treatment for ptosis.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on RevitaLid Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RevitaLid Pharmaceutical.

Explore the full profile